Stock Financial Ratios and Split History
WVE / WAVE Life Sciences Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||1,161.68|
|Enterprise Value ($M)||1,019.18|
|Book Value ($M)||139.81|
|Book Value / Share||4.99|
|Price / Book||8.31|
|NCAV / Share||4.43|
|Price / NCAV||9.07|
|Income Statement (mra) ($M)|
|Balance Sheet (mrq) ($M)|
|Cash & Equivalents||0.00|
|Cash / Share||0.00|
|Common Stock Shares Outstanding||27,829,079|
|Temporary Equity Shares Outstanding||3,901,348|
|Common Shares Outstanding||27,992,244|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Cash Conversion Cycle||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-0.73|
|Return on Assets (ROA)||-0.62|
|Return on Equity (ROE)||-0.76|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1631574|
|SIC 2834 - Pharmaceutical Preparations|
Stock splits are used by WAVE Life Sciences Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Peers - Pharmaceutical Preparations (2834)
ENDV / Endonovo Therapeutics, Inc.
AXIM / Axim Biotechnologies, Inc.
PRTT / Protect Pharmaceutical Corp
NNAB / NanoAntibiotics, Inc.
Related News Stories
Today we will discuss Portola Pharmaceuticals (PTLA), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. (227-4)
Ionis's trials for Alzheimer's, Parkinson's, ALS and Huntington's may produce the first therapies for these previous "undruggable" disorders. (123-1)
Shares rose by as much as 225% in the past six months before the recent pullback. (19-1)
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (381-11)
It is thought that significantly improved exon 51 skipping efficiency and dystrophin protein restoration observed in preclinical studies could translate into an improved second-generation treatment. (32-1)